ArticlePeerJ2025
Effect of circadian rhythm disruption on benign prostatic hyperplasia in rats.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is a common condition in middle-aged and elderly men. Disrupted circadian rhythms (CRD) can directly influence aging, inflammation, metabolic syndrome, and hormonal changes-all of which are closely linked to BPH. This study aimed to investigate whether CRD accelerates prostatic hyperplasia in rats. Twenty male Sprague-Dawley (SD) rats were divided into two batches. A BPH model was established using mixed slow-release pellets of testosterone (T) and estradiol (E2). CRD was induced by continuous light exposure (Cle), while a 12-hour light/12-hour dark cycle defined the control (Con) group. First batch: Rats were divided into T+E2 and T+E2+Cle groups. Initial and final body weight, prostate weight, and prostate index (PI) were recorded. Hematoxylin and eosin (H&E) staining was performed. Serum levels of dihydrotestosterone (DHT) and estradiol (E2) were measured by ELISA, and mRNA expression of circadian rhythm genes was assessed via qRT-PCR. Second batch: Rats were divided into Con and Cle groups. Body weight, prostate weight, and PI were recorded. H&E staining was used for pathological analysis. Ki-67 expression was assessed by immunohistochemistry (IHC). RNA sequencing (RNA-Seq) was used to investigate gene expression in prostate tissue, validated by qRT-PCR. Differentially expressed genes (DEGs) were analyzed using bioinformatics methods. First batch results: CRD significantly increased prostate weight, PI, and epithelial thickness; elevated serum DHT levels; and reduced E2 levels. qRT-PCR confirmed that CRD altered circadian gene expression. Second batch results: CRD significantly increased PI and Ki-67 expression in the prostate. GO analysis revealed significant enrichment in immune response, external side of plasma membrane, and carbohydrate binding ( Conclusion: These findings suggest that CRD may accelerate prostate cell growth by modulating immune and inflammatory responses, contributing to the development of benign prostatic hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.